Xbrane Biopharma AB Strengthens its Management Team to Better Equip the Company for Commercialization of Its Biosimilars
February 21, 2020 at 09:00 am EST
Share
Xbrane Biopharma strengthens its management team to better equip the company for commercialization of its biosimilars. Maria Edebrink, Head of Regulatory Affairs, with over 28 years of experience from AstraZeneca, Galderma and Medivir, will form part of the management team as of February 21, 2020. Anders Wallström, Head of Manufacturing and Supply Chain, with over 19 years of commercial supply chain experience from SOBI and Biovitrum, will form part of the management team as of February 21, 2020. Xiaoli Hu, recently recruited as Head of Business Development, with experience from Affibody and HealthCap, will join Xbrane and form part of the management team as of May 1, 2020. Paolo Sarmientos, Head of long-acting injectables and CEO of Xbrane's subsidiary Primm Pharma, will, provided Xbrane’s strategic focus on biosimilars, no longer form part of the management team as of February 21, 2020. Maria Edebrink joined Xbrane during 2019 as Head of Regulatory Affairs and has since then led the preparatory work for Marketing Authorization Application for Xlucane in Europe and the US. Maria has altogether over 28 years of experience from Pharmaceutical Development and Regulatory Affairs from AstraZeneca, Galderma and Medivir. Anders Wallström joined Xbrane during 2019 as Head of Manufacturing and Supply Chain and has since worked with the establishment of the commercial supply chain for Xlucane. Anders has over 19 years of experience from process development, manufacturing and validation of biological products at SOBI and Biovitrum. In Anders last role at SOBI he was end-to-end supply chain director for specialty care products including Kineret® and Orfadin®. Xiaoli Hu will join Xbrane as Head of Business Development on May 1, 2020 and will then be part of the management team. She will be primarily responsible for the establishment of new partnerships for commercialization of Xbrane’s pre-clinical biosimilars. Xiaoli has gained first-hand experience in business development from the pharmaceutical industry, most recently as Business Development Director at Affibody, where she led the work towards the USD 650 million commercial partnership deal with Alexion and the co-development deal with GE Healthcare. Prior to that, Xiaoli spent nearly four years at HealthCap.
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
XBRANE BIOPHARMA AB 
